kyorin 600

Sunday, November 21, 2021
11:45 a.m. - 12:45 p.m. JST (Japan Standard Time - UTC+9)

Industry Sponsored Session by KYORIN Pharmaceutical Co., Ltd.

A novel therapeutic application of Beta3 adrenergic receptor agonist for erectile dysfunction

In 1999, we have presented the 1st paper regarding beta-3 adrenergic receptor (b3) and relaxation of human urinary bladder [1]. We have also found the gene expression of b3 in human corpus cavernosum [not published]. In 2003, 1st paper regarding b3 and the function of human corpus cavernosum has been published [2]. Vibegron is a potent, selective b3 adrenergic receptor b3 agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity, was first approved in Japan in September 2018 for the treatment of overactive bladder (OAB) under market name BEOVA® [3], and was approved for OAB under the market name GEMTESA® in USA 2020. Unlike Mirabegron, which was first approved b3 agonist for OAB, Vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes. In addition to OAB, erectile dysfunction is a new application field of Vibegron, a new b3 agonist. In this satellite session, we will review and discuss the possibility of Vibegron for the treatment of erectile dysfunction.

1.Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. M Takeda, et al., J Pharmacol Exp Ther. 1999 Mar;288(3):1367-73.

2.Involvement of BETA3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Cirino G, et al., PNAS April 29, 2003 100 (9) 5531-5536.

3. Vibegron, a Novel Potent and Selective b3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study, European Urology, Volume 73, Issue 5, May 2018, Pages 783-790. Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T.

Speaker
Masayuki Takeda, M.D., Ph.D.
Visiting Professor, Professor Emeritus, Department of Urology, Faculty of Medicine. Honorary Director of University Hospital/Vice President of Honorary Institute, University of Yamanashi   

Moderator
Takashi Fukagai, M.D., Ph.D.
Professor, Department of Urology, Faculty of Medicine, Showa University  

Dr. Masayuki Takeda
Dr. Masayuki Takeda Japan
Dr. Masayuki Takeda is a Visiting Professor, Professor Emeritus, Department of Urology, Faculty of Medicine, University of Yamanashi. He is also Honorary Director of University Hospital/Vice President of Honorary Institute University of Yamanashi. He has research interests in molecular pharmacology of urinary tract and sexual organs, and minimally-invasive surgery. Dr. Takeda is currently serving on the member of 1st Section of Pharmaceutical Affairs and Food Sanitation Council, the Japanese Ministry of Health, Labour, and Welfare.
Dr. Takashi Fukagai
Dr. Takashi FukagaiJapan
Dr. Takashi Fukagai is professor of urology in Showa University, School of Medicine Tokyo, Japan. He graduated from the Showa University School of Medicine in 1986, He did his research at the University of Hawaii and the Queen’s Medical Center at Honolulu studying prostate pathology and epidemiology. He is an active member of several oncological and urological societies in Japan and is currently president of Prostate Education Council in Japan (PCEC-Japan). He became president of the Asian Pacific Prostate Society (APPS) on January 1st in 2021. His special interests are in prostate cancer, especially for ethnic difference of prostate cancer. His most recent work has focused on brachytherapy, robotic surgery, and PSA screening in Japan.

Print